Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study
Tóm tắt
From January 1980 to August 1982 the Cancer and Leukemia Group B conducted a prospective randomized trial comparing chemoendocrine therapy with T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen) to CAF alone in postmenopausal women with advanced breast cancer. The patients were stratified by estrogen receptor (ER) status into three groups: ER-negative, ER-positive, ER-unknown. They were also stratified by dominant site of metastatic disease: visceral and other (osseous and/or soft tissue). A total of 246 eligible patients were enrolled in the study; 232 were evaluable and constitute the basis for this report. The study revealed that there was no difference in overall response frequency or response duration between T-CAF and CAF; there was no difference in response between T-CAF and CAF in ER-positive or in ER-negative patients; and there was no difference in response between T-CAF and CAF by dominant site of metastatic disease. The expected advantage of T-CAF over CAF, especially for ER-positive patients, was not observed.
Tài liệu tham khảo
Kardinal CG: Chemotherapy.In WL Donegan, JS Spratt (eds). Cancer of the Breast. Saunders, Philadelphia, 1979, pp 405–447
Greenspan EM, Fieber M, Lesnick G, Edelman S: Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating agent, thiotepa. J Mt Sinai Hosp 30:246–267, 1963
Cooper R: Combination chemotherapy in hormone resistant breast cancer (Abstract). Proc Am Assoc Cancer Res 10:15, 1969
Kardinal CG, Donegan WL: Endocrine and hormonal therapy.In WL Donegan, JS Spratt (eds). Cancer of the Breast. Saunders, Philadelphia, 1979, pp 361–404
Greene GL, Jensen EV: The use of monoclonal antibodies in estrogen receptor assays (Abstract). Proc 13th Int Cancer Congress, Seattle, Washington, September 8–15, 1982, p 573
Mercer WD, Lippman ME, Wahl TM, Carlson CA, Wahl DA, Legotte D, Teague PO: The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. Cancer 46:2859–2868, 1980
Hilf R, Wittliff JL, Rector WD, Savlov ED, Hall TC, Orlando RA: Studies on certain cytoplasmic enzymes and specific estrogen receptors in human breast cancer and in nonmalignant diseases of the breast. Cancer Res 33:2054–2062, 1973
Lippman ME, Allegra JC: Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2829–2834, 1980
Cocconi G, DeLisa V, Mori P, Malacarne P, Amadori D, Giovanelli E: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: a randomized study. Cancer 51:581–588, 1983
Mouridsen HT, Palshof T, Engelsman E, Sylvester R: CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.In HT Mouridsen, T Palshof (eds). Breast Cancer — Experimental and Clinical Aspects. Pergamon Press, Oxford, 1980, pp 119–123
Ahmann FR, Jones SE, Moon TE, Davis SL, Salmon SE: Improved survival of patients with advanced breast cancer treated with adriamycin-cyclophosphamide plus tamoxifen (TAC) (Abstract). Proc AACR/ASCO 22:148, 1981
Tormey DC, Falkson HC, Falkson G, Voelkel J, Crowley J, Davis TE: Dibromoducitol and adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33–39, 1982
Osborne CK: Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat 1:121–123, 1981